TBPH · As filed with the SEC
Theravance Biopharma income statement, by fiscal year
The statement as Theravance Biopharma presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF OPERATIONS · USD, except per-share amounts
| USD, except per-share amounts | FY2025 Year ended Dec 31, 2025 | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 |
|---|---|---|---|---|
| Revenues: | ||||
| Total revenues | 107,464,000 | 64,381,000 | 57,424,000 | 51,346,000 |
| Viatris collaboration agreement | — | 64,381,000 | 57,201,000 | 48,624,000 |
| Viatris royalties (Non-US) | — | — | 7,000 | 30,000 |
| Licensing and Milestone | 32,500,000 | — | — | — |
| Collaboration Agreement | 74,964,000 | — | 216,000 | 192,000 |
| Licensing revenue | — | — | — | 2,500,000 |
| Expenses: | ||||
| Research and development | 37,414,000 | 37,643,000 | 40,621,000 | 63,392,000 |
| Selling, general and administrative | 73,652,000 | 69,174,000 | 70,095,000 | 67,073,000 |
| Impairment of long-lived assets (non-cash) | — | 4,513,000 | — | — |
| Restructuring and related expenses | — | — | 2,743,000 | 12,838,000 |
| Selling, general and administrative | — | — | — | 6,900,000 |
| Research and development | — | — | — | 5,900,000 |
| Impairment of long-lived assets (non-cash) | 0 | — | — | — |
| Total expenses | 111,066,000 | 111,330,000 | 113,459,000 | 143,303,000 |
| Loss from operations | (3,602,000) | (46,949,000) | (56,035,000) | (91,957,000) |
| Interest expense | — | — | (2,350,000) | (6,369,000) |
| Loss on extinguishment of debt | — | — | — | (3,034,000) |
| Net gain on realized contingent milestone and royalty assets | 75,137,000 | — | — | — |
| TRELEGY milestone income | 50,000,000 | — | — | — |
| Interest expense (non-cash) | (2,461,000) | (2,546,000) | — | — |
| Interest and other income, net | 10,173,000 | 4,881,000 | 9,116,000 | 8,545,000 |
| Income (loss) before income taxes | 129,247,000 | (44,614,000) | (49,269,000) | (92,815,000) |
| Provision for income tax benefit (expense) | (23,352,000) | (11,804,000) | (5,924,000) | (9,000) |
| Net loss from continuing operations | — | — | (55,193,000) | (92,824,000) |
| Income from discontinued operations before income taxes | — | — | — | 1,143,930,000 |
| Provision for income tax expense | — | — | — | (178,974,000) |
| Net income from discontinued operations | — | — | — | 964,956,000 |
| Net income (loss) | 105,895,000 | (56,418,000) | (55,193,000) | 872,132,000 |
| Continuing operations - basic (in dollars per share) | — | — | (1.00) | (1.26) |
| Continuing operations - diluted (in dollars per share) | — | — | (1.00) | (1.26) |
| Discontinued operations - basic (in dollars per share) | — | — | — | 13.11 |
| Discontinued operations - diluted (in dollars per share) | — | — | — | 13.11 |
| Net income (loss) per share: | ||||
| Net income (loss) per share - basic (in dollars per share) | 2.10 | (1.15) | (1.00) | 11.85 |
| Net income (loss) per share - diluted (in dollars per share) | 2.06 | (1.15) | (1.00) | 11.85 |
| Shares used to compute net income (loss) per share - basic (in shares) | 50,317,000 | 48,847,000 | 55,303,000 | 73,591,000 |
| Shares used to compute net income (loss) per share - diluted (in shares) | 51,507,000 | 48,847,000 | 55,303,000 | 73,591,000 |
| Total share-based compensation expense | — | — | — | 39,734,000 |
| Research and development | — | — | — | 12,888,000 |
| Selling, general and administrative | — | — | — | 19,848,000 |
| Restructuring and related expenses | — | — | — | 6,998,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.